ES2980685T3 - Derivados de 4-(p-quinonil)-2-hidroxibutanamida para el tratamiento de enfermedades mitocondriales - Google Patents

Derivados de 4-(p-quinonil)-2-hidroxibutanamida para el tratamiento de enfermedades mitocondriales Download PDF

Info

Publication number: ES2980685T3
Authority: ES; Spain
Prior art keywords: hydroxy; alkyl; aryl; methyl; butanamide
Prior art date: 2007-11-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES20169398T

Other languages

English (en)

Spanish (es)

Inventor

Orion Jankowski

Kieron Wesson

Paul Mollard

William Shrader

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

PTC Therapeutics Inc

Original Assignee

PTC Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-11-06

Filing date

2008-11-04

Publication date

2024-10-02

2008-11-04 Application filed by PTC Therapeutics Inc filed Critical PTC Therapeutics Inc

2024-10-02 Application granted granted Critical

2024-10-02 Publication of ES2980685T3 publication Critical patent/ES2980685T3/es

Status Active legal-status Critical Current

2028-11-04 Anticipated expiration legal-status Critical

Links

208000012268 mitochondrial disease Diseases 0.000 title claims abstract description 67
238000011282 treatment Methods 0.000 title claims description 26
150000001875 compounds Chemical class 0.000 claims abstract description 221
239000000203 mixture Substances 0.000 claims abstract description 97
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 90
208000024412 Friedreich ataxia Diseases 0.000 claims abstract description 39
208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 claims abstract description 33
206010048804 Kearns-Sayre syndrome Diseases 0.000 claims abstract description 30
201000000639 Leber hereditary optic neuropathy Diseases 0.000 claims abstract description 30
208000018737 Parkinson disease Diseases 0.000 claims abstract description 25
208000029560 autism spectrum disease Diseases 0.000 claims abstract description 24
201000002169 Mitochondrial myopathy Diseases 0.000 claims abstract description 21
208000012202 Pervasive developmental disease Diseases 0.000 claims abstract description 21
206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims abstract description 21
208000020706 Autistic disease Diseases 0.000 claims abstract description 16
208000023692 inborn mitochondrial myopathy Diseases 0.000 claims abstract description 16
208000014644 Brain disease Diseases 0.000 claims abstract description 12
208000032274 Encephalopathy Diseases 0.000 claims abstract description 12
208000023105 Huntington disease Diseases 0.000 claims abstract description 12
239000000090 biomarker Substances 0.000 claims description 126
238000000034 method Methods 0.000 claims description 93
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 85
229910052739 hydrogen Inorganic materials 0.000 claims description 73
239000001257 hydrogen Substances 0.000 claims description 67
201000010099 disease Diseases 0.000 claims description 60
-1 cycloalkyl-C3-C6 Chemical group 0.000 claims description 47
125000003118 aryl group Chemical group 0.000 claims description 43
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 43
125000000623 heterocyclic group Chemical group 0.000 claims description 34
125000001072 heteroaryl group Chemical group 0.000 claims description 32
229910052757 nitrogen Inorganic materials 0.000 claims description 26
229910052760 oxygen Inorganic materials 0.000 claims description 26
125000000304 alkynyl group Chemical group 0.000 claims description 23
125000000217 alkyl group Chemical group 0.000 claims description 22
125000003342 alkenyl group Chemical group 0.000 claims description 21
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 20
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 19
125000004043 oxo group Chemical group O=* 0.000 claims description 19
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 18
239000001301 oxygen Substances 0.000 claims description 18
201000009035 MERRF syndrome Diseases 0.000 claims description 17
208000024825 childhood disintegrative disease Diseases 0.000 claims description 16
239000003814 drug Substances 0.000 claims description 16
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
125000004433 nitrogen atom Chemical group N* 0.000 claims description 16
238000006467 substitution reaction Methods 0.000 claims description 16
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
201000009623 Myopathy Diseases 0.000 claims description 14
230000001629 suppression Effects 0.000 claims description 14
125000003545 alkoxy group Chemical group 0.000 claims description 13
208000006289 Rett Syndrome Diseases 0.000 claims description 12
239000008194 pharmaceutical composition Substances 0.000 claims description 12
125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 10
208000006136 Leigh Disease Diseases 0.000 claims description 10
208000017507 Leigh syndrome Diseases 0.000 claims description 10
125000005842 heteroatom Chemical group 0.000 claims description 10
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 9
239000000546 pharmaceutical excipient Substances 0.000 claims description 9
208000024827 Alzheimer disease Diseases 0.000 claims description 8
208000036640 Asperger disease Diseases 0.000 claims description 8
201000006062 Asperger syndrome Diseases 0.000 claims description 8
208000036353 Rett disease Diseases 0.000 claims description 8
229920006395 saturated elastomer Polymers 0.000 claims description 8
239000003981 vehicle Substances 0.000 claims description 8
208000012902 Nervous system disease Diseases 0.000 claims description 7
125000004429 atom Chemical group 0.000 claims description 7
239000003937 drug carrier Substances 0.000 claims description 7
150000002367 halogens Chemical class 0.000 claims description 7
208000005264 motor neuron disease Diseases 0.000 claims description 7
208000015122 neurodegenerative disease Diseases 0.000 claims description 7
125000001424 substituent group Chemical group 0.000 claims description 7
208000025966 Neurological disease Diseases 0.000 claims description 6
229910052799 carbon Inorganic materials 0.000 claims description 6
206010012601 diabetes mellitus Diseases 0.000 claims description 6
206010015037 epilepsy Diseases 0.000 claims description 6
229910052736 halogen Inorganic materials 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
125000004430 oxygen atom Chemical group O* 0.000 claims description 6
201000010384 renal tubular acidosis Diseases 0.000 claims description 6
229910052717 sulfur Inorganic materials 0.000 claims description 6
125000004434 sulfur atom Chemical group 0.000 claims description 6
208000020925 Bipolar disease Diseases 0.000 claims description 5
208000031229 Cardiomyopathies Diseases 0.000 claims description 5
208000026350 Inborn Genetic disease Diseases 0.000 claims description 5
206010058799 Mitochondrial encephalomyopathy Diseases 0.000 claims description 5
208000019022 Mood disease Diseases 0.000 claims description 5
206010028980 Neoplasm Diseases 0.000 claims description 5
201000011510 cancer Diseases 0.000 claims description 5
208000016361 genetic disease Diseases 0.000 claims description 5
208000002780 macular degeneration Diseases 0.000 claims description 5
230000004770 neurodegeneration Effects 0.000 claims description 5
201000000980 schizophrenia Diseases 0.000 claims description 5
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
239000011593 sulfur Substances 0.000 claims description 4
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
108010016626 Dipeptides Proteins 0.000 claims description 3
125000002877 alkyl aryl group Chemical group 0.000 claims description 3
125000004432 carbon atom Chemical group C* 0.000 claims description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
208000026072 Motor neurone disease Diseases 0.000 claims 1
125000004122 cyclic group Chemical group 0.000 claims 1
125000001188 haloalkyl group Chemical group 0.000 claims 1
229930195734 saturated hydrocarbon Natural products 0.000 claims 1
208000035475 disorder Diseases 0.000 abstract description 30
208000006011 Stroke Diseases 0.000 abstract description 22
208000006443 lactic acidosis Diseases 0.000 abstract description 9
206010003805 Autism Diseases 0.000 abstract description 7
DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 199
238000005160 1H NMR spectroscopy Methods 0.000 description 75
XMPZTFVPEKAKFH-UHFFFAOYSA-P ceric ammonium nitrate Chemical compound [NH4+].[NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O XMPZTFVPEKAKFH-UHFFFAOYSA-P 0.000 description 74
239000000243 solution Substances 0.000 description 63
210000004027 cell Anatomy 0.000 description 51
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 41
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 40
239000007787 solid Substances 0.000 description 35
ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 34
230000003647 oxidation Effects 0.000 description 34
238000007254 oxidation reaction Methods 0.000 description 34
RLNWRDKVJSXXPP-UHFFFAOYSA-N tert-butyl 2-[(2-bromoanilino)methyl]piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1CNC1=CC=CC=C1Br RLNWRDKVJSXXPP-UHFFFAOYSA-N 0.000 description 34
235000017471 coenzyme Q10 Nutrition 0.000 description 33
208000024891 symptom Diseases 0.000 description 33
239000003921 oil Substances 0.000 description 32
235000019198 oils Nutrition 0.000 description 32
150000001408 amides Chemical class 0.000 description 31
230000008878 coupling Effects 0.000 description 31
238000010168 coupling process Methods 0.000 description 31
238000005859 coupling reaction Methods 0.000 description 31
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 25
102000018832 Cytochromes Human genes 0.000 description 25
108010052832 Cytochromes Proteins 0.000 description 25
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 24
KJQFBVYMGADDTQ-CVSPRKDYSA-N L-buthionine-(S,R)-sulfoximine Chemical compound CCCCS(=N)(=O)CC[C@H](N)C(O)=O KJQFBVYMGADDTQ-CVSPRKDYSA-N 0.000 description 24
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
230000002829 reductive effect Effects 0.000 description 23
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 21
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 21
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 21
229910052938 sodium sulfate Inorganic materials 0.000 description 21
235000011152 sodium sulphate Nutrition 0.000 description 21
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 20
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 20
239000007832 Na2SO4 Substances 0.000 description 19
210000004369 blood Anatomy 0.000 description 19
239000008280 blood Substances 0.000 description 19
238000006243 chemical reaction Methods 0.000 description 19
210000002950 fibroblast Anatomy 0.000 description 19
238000003818 flash chromatography Methods 0.000 description 19
LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 18
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
229940076788 pyruvate Drugs 0.000 description 18
XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 16
210000001175 cerebrospinal fluid Anatomy 0.000 description 16
239000002609 medium Substances 0.000 description 16
230000035806 respiratory chain Effects 0.000 description 16
150000003839 salts Chemical class 0.000 description 16
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
239000002253 acid Substances 0.000 description 15
235000019439 ethyl acetate Nutrition 0.000 description 15
230000006872 improvement Effects 0.000 description 15
DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 14
230000000694 effects Effects 0.000 description 14
210000001519 tissue Anatomy 0.000 description 14
239000002904 solvent Substances 0.000 description 13
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
230000037396 body weight Effects 0.000 description 12
230000003247 decreasing effect Effects 0.000 description 12
230000004065 mitochondrial dysfunction Effects 0.000 description 12
210000002381 plasma Anatomy 0.000 description 12
239000000843 powder Substances 0.000 description 12
238000002560 therapeutic procedure Methods 0.000 description 12
150000002431 hydrogen Chemical group 0.000 description 11
238000010606 normalization Methods 0.000 description 11
238000012360 testing method Methods 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 10
206010003591 Ataxia Diseases 0.000 description 10
ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 10
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 10
230000009286 beneficial effect Effects 0.000 description 10
229910002092 carbon dioxide Inorganic materials 0.000 description 10
230000002490 cerebral effect Effects 0.000 description 10
230000007812 deficiency Effects 0.000 description 10
239000012530 fluid Substances 0.000 description 10
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 10
230000000241 respiratory effect Effects 0.000 description 10
235000017557 sodium bicarbonate Nutrition 0.000 description 10
229910000030 sodium bicarbonate Inorganic materials 0.000 description 10
208000021642 Muscular disease Diseases 0.000 description 9
WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 description 9
239000008346 aqueous phase Substances 0.000 description 9
230000001965 increasing effect Effects 0.000 description 9
239000000523 sample Substances 0.000 description 9
230000002861 ventricular Effects 0.000 description 9
BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 8
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 8
230000001684 chronic effect Effects 0.000 description 8
210000003470 mitochondria Anatomy 0.000 description 8
239000012074 organic phase Substances 0.000 description 8
238000012216 screening Methods 0.000 description 8
238000003756 stirring Methods 0.000 description 8
206010010904 Convulsion Diseases 0.000 description 7
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 7
210000004556 brain Anatomy 0.000 description 7
239000001569 carbon dioxide Substances 0.000 description 7
229940110767 coenzyme Q10 Drugs 0.000 description 7
230000002950 deficient Effects 0.000 description 7
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 7
239000007788 liquid Substances 0.000 description 7
229950006238 nadide Drugs 0.000 description 7
230000010627 oxidative phosphorylation Effects 0.000 description 7
239000012071 phase Substances 0.000 description 7
229950007002 phosphocreatine Drugs 0.000 description 7
239000011541 reaction mixture Substances 0.000 description 7
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 6
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
230000001154 acute effect Effects 0.000 description 6
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
238000004113 cell culture Methods 0.000 description 6
230000004064 dysfunction Effects 0.000 description 6
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 6
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
239000002502 liposome Substances 0.000 description 6
238000005259 measurement Methods 0.000 description 6
230000002503 metabolic effect Effects 0.000 description 6
230000001575 pathological effect Effects 0.000 description 6
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 6
239000000725 suspension Substances 0.000 description 6
230000035899 viability Effects 0.000 description 6
KVZLHPXEUGJPAH-UHFFFAOYSA-N 2-oxidanylpropanoic acid Chemical compound CC(O)C(O)=O.CC(O)C(O)=O KVZLHPXEUGJPAH-UHFFFAOYSA-N 0.000 description 5
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
230000002411 adverse Effects 0.000 description 5
239000003963 antioxidant agent Chemical class 0.000 description 5
235000006708 antioxidants Nutrition 0.000 description 5
230000008901 benefit Effects 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
230000007423 decrease Effects 0.000 description 5
230000002500 effect on skin Effects 0.000 description 5
239000000839 emulsion Substances 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
239000006260 foam Substances 0.000 description 5
238000009472 formulation Methods 0.000 description 5
239000008103 glucose Substances 0.000 description 5
230000036541 health Effects 0.000 description 5
208000014674 injury Diseases 0.000 description 5
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
239000004310 lactic acid Substances 0.000 description 5
235000014655 lactic acid Nutrition 0.000 description 5
230000036284 oxygen consumption Effects 0.000 description 5
229940124597 therapeutic agent Drugs 0.000 description 5
230000004102 tricarboxylic acid cycle Effects 0.000 description 5
XXFLYELFTZOCRJ-UHFFFAOYSA-N (2-carbonochloridoyl-2,5,7,8-tetramethyl-3,4-dihydrochromen-6-yl) acetate Chemical compound O1C(C)(C(Cl)=O)CCC2=C(C)C(OC(=O)C)=C(C)C(C)=C21 XXFLYELFTZOCRJ-UHFFFAOYSA-N 0.000 description 4
125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 4
AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 4
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
HWKRAUXFMLQKLS-UHFFFAOYSA-N 2-oxidanylidenepropanoic acid Chemical compound CC(=O)C(O)=O.CC(=O)C(O)=O HWKRAUXFMLQKLS-UHFFFAOYSA-N 0.000 description 4
BVYZEFLWUAIZRH-UHFFFAOYSA-N 6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromene-2-carboxamide Chemical class O1C(C)(C(N)=O)CCC2=C1C(C)=C(C)C(O)=C2C BVYZEFLWUAIZRH-UHFFFAOYSA-N 0.000 description 4
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
102000009024 Epidermal Growth Factor Human genes 0.000 description 4
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 4
206010050029 Mitochondrial cytopathy Diseases 0.000 description 4
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
BOPGDPNILDQYTO-NNYOXOHSSA-L NADH(2-) Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-L 0.000 description 4
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical group C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 4
230000004103 aerobic respiration Effects 0.000 description 4
230000004099 anaerobic respiration Effects 0.000 description 4
238000003556 assay Methods 0.000 description 4
BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 4
230000000747 cardiac effect Effects 0.000 description 4
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
230000006378 damage Effects 0.000 description 4
230000002708 enhancing effect Effects 0.000 description 4
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 description 4
229960004135 idebenone Drugs 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
230000008811 mitochondrial respiratory chain Effects 0.000 description 4
210000003205 muscle Anatomy 0.000 description 4
IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
230000036542 oxidative stress Effects 0.000 description 4
230000036961 partial effect Effects 0.000 description 4
239000006187 pill Substances 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
230000008569 process Effects 0.000 description 4
230000002035 prolonged effect Effects 0.000 description 4
239000003642 reactive oxygen metabolite Substances 0.000 description 4
NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 4
230000009467 reduction Effects 0.000 description 4
238000011160 research Methods 0.000 description 4
241000894007 species Species 0.000 description 4
239000011550 stock solution Substances 0.000 description 4
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
239000006188 syrup Substances 0.000 description 4
235000020357 syrup Nutrition 0.000 description 4
239000003826 tablet Substances 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
239000011782 vitamin Substances 0.000 description 4
229940088594 vitamin Drugs 0.000 description 4
235000013343 vitamin Nutrition 0.000 description 4
229930003231 vitamin Natural products 0.000 description 4
BAANPNDZFYBQIB-UHFFFAOYSA-N 2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide Chemical class CC1=C(C)C(=O)C(CCC(C)(O)C(N)=O)=C(C)C1=O BAANPNDZFYBQIB-UHFFFAOYSA-N 0.000 description 3
WHBMMWSBFZVSSR-UHFFFAOYSA-M 3-hydroxybutyrate Chemical compound CC(O)CC([O-])=O WHBMMWSBFZVSSR-UHFFFAOYSA-M 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
201000004569 Blindness Diseases 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
208000010354 Coenzyme Q10 deficiency Diseases 0.000 description 3
206010012289 Dementia Diseases 0.000 description 3
206010012559 Developmental delay Diseases 0.000 description 3
108010024882 Electron Transport Complex III Proteins 0.000 description 3
102000015782 Electron Transport Complex III Human genes 0.000 description 3
206010021118 Hypotonia Diseases 0.000 description 3
102000004877 Insulin Human genes 0.000 description 3
108090001061 Insulin Proteins 0.000 description 3
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
208000007379 Muscle Hypotonia Diseases 0.000 description 3
238000004497 NIR spectroscopy Methods 0.000 description 3
YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
208000004756 Respiratory Insufficiency Diseases 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 3
230000002159 abnormal effect Effects 0.000 description 3
230000005856 abnormality Effects 0.000 description 3
239000013543 active substance Substances 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
230000004087 circulation Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000006735 deficit Effects 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
238000000605 extraction Methods 0.000 description 3
206010016256 fatigue Diseases 0.000 description 3
239000012894 fetal calf serum Substances 0.000 description 3
239000000835 fiber Substances 0.000 description 3
239000007789 gas Substances 0.000 description 3
230000034659 glycolysis Effects 0.000 description 3
239000003701 inert diluent Substances 0.000 description 3
229940125396 insulin Drugs 0.000 description 3
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 description 3
GVZFUVXPTPGOQT-UHFFFAOYSA-M mitoq Chemical compound CS([O-])(=O)=O.O=C1C(OC)=C(OC)C(=O)C(CCCCCCCCCC[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1C GVZFUVXPTPGOQT-UHFFFAOYSA-M 0.000 description 3
230000035772 mutation Effects 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
206010030875 ophthalmoplegia Diseases 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
230000037081 physical activity Effects 0.000 description 3
230000000750 progressive effect Effects 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
201000004193 respiratory failure Diseases 0.000 description 3
230000004044 response Effects 0.000 description 3
230000000284 resting effect Effects 0.000 description 3
210000002027 skeletal muscle Anatomy 0.000 description 3
239000000375 suspending agent Substances 0.000 description 3
208000011580 syndromic disease Diseases 0.000 description 3
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
229940035936 ubiquinone Drugs 0.000 description 3
RNHVYXAGIRNPGG-UHFFFAOYSA-N (6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)-piperidin-1-ylmethanone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)C(=O)N1CCCCC1 RNHVYXAGIRNPGG-UHFFFAOYSA-N 0.000 description 2
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical group C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 2
QIXDHVDGPXBRRD-UHFFFAOYSA-N 2,3,5-trimethylcyclohexa-2,5-diene-1,4-dione Chemical compound CC1=CC(=O)C(C)=C(C)C1=O QIXDHVDGPXBRRD-UHFFFAOYSA-N 0.000 description 2
DHYJSHILHSHPHP-UHFFFAOYSA-N 2-(3-hydroxy-3-methyl-4-oxo-4-piperidin-1-ylbutyl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C(C)=C(C)C(=O)C(CCC(C)(O)C(=O)N2CCCCC2)=C1C DHYJSHILHSHPHP-UHFFFAOYSA-N 0.000 description 2
WMKSYSBVGRPFNM-UHFFFAOYSA-N 2-[4-(4-acetylpiperazin-1-yl)-3-hydroxy-3-methyl-4-oxobutyl]-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione Chemical compound C1CN(C(=O)C)CCN1C(=O)C(C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O WMKSYSBVGRPFNM-UHFFFAOYSA-N 0.000 description 2
NZTUDHWGKIMDSD-UHFFFAOYSA-N 2-[4-(4-benzylpiperazin-1-yl)-3-hydroxy-3-methyl-4-oxobutyl]-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C(C)=C(C)C(=O)C(CCC(C)(O)C(=O)N2CCN(CC=3C=CC=CC=3)CC2)=C1C NZTUDHWGKIMDSD-UHFFFAOYSA-N 0.000 description 2
GOJQQMCDZIJTEP-UHFFFAOYSA-N 2-hydroxy-2-methyl-n-(2-pyridin-2-ylethyl)-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide Chemical compound O=C1C(C)=C(C)C(=O)C(CCC(C)(O)C(=O)NCCC=2N=CC=CC=2)=C1C GOJQQMCDZIJTEP-UHFFFAOYSA-N 0.000 description 2
WPGQBIUQNUJYCQ-UHFFFAOYSA-N 2-hydroxy-2-methyl-n-(pyridin-2-ylmethyl)-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide Chemical compound O=C1C(C)=C(C)C(=O)C(CCC(C)(O)C(=O)NCC=2N=CC=CC=2)=C1C WPGQBIUQNUJYCQ-UHFFFAOYSA-N 0.000 description 2
QVQKBCCJCUVXPA-UHFFFAOYSA-N 2-hydroxy-2-methyl-n-[3-(2-oxopyrrolidin-1-yl)propyl]-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide Chemical compound O=C1C(C)=C(C)C(=O)C(CCC(C)(O)C(=O)NCCCN2C(CCC2)=O)=C1C QVQKBCCJCUVXPA-UHFFFAOYSA-N 0.000 description 2
HNDAUTXEFVPLLV-UHFFFAOYSA-N 2-hydroxy-n-(1-hydroxypropan-2-yl)-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide Chemical compound OCC(C)NC(=O)C(C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O HNDAUTXEFVPLLV-UHFFFAOYSA-N 0.000 description 2
VLIAPFJRVHLZRF-UHFFFAOYSA-N 2-hydroxy-n-(2-hydroxypropyl)-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide Chemical compound CC(O)CNC(=O)C(C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O VLIAPFJRVHLZRF-UHFFFAOYSA-N 0.000 description 2
DKBOCYFAYQVCDX-UHFFFAOYSA-N 2-hydroxy-n-(4-hydroxybutyl)-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide Chemical compound CC1=C(C)C(=O)C(CCC(C)(O)C(=O)NCCCCO)=C(C)C1=O DKBOCYFAYQVCDX-UHFFFAOYSA-N 0.000 description 2
LDKUKIDKPWSTMD-UHFFFAOYSA-N 2-hydroxy-n-(6-hydroxyhexyl)-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide Chemical compound CC1=C(C)C(=O)C(CCC(C)(O)C(=O)NCCCCCCO)=C(C)C1=O LDKUKIDKPWSTMD-UHFFFAOYSA-N 0.000 description 2
DCGQEWREDCYBSF-UHFFFAOYSA-N 2-hydroxy-n-[2-(2-hydroxyethoxy)ethyl]-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide Chemical compound CC1=C(C)C(=O)C(CCC(C)(O)C(=O)NCCOCCO)=C(C)C1=O DCGQEWREDCYBSF-UHFFFAOYSA-N 0.000 description 2
DGWQQRLFELGLHL-UHFFFAOYSA-N 2-hydroxy-n-methoxy-n,2-dimethyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide Chemical compound CON(C)C(=O)C(C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O DGWQQRLFELGLHL-UHFFFAOYSA-N 0.000 description 2
ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 2
KDSNLYIMUZNERS-UHFFFAOYSA-N 2-methylpropanamine Chemical compound CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 description 2
CUHJERIEOYEEOS-UHFFFAOYSA-N 6-acetyloxy-2,5,7,8-tetramethyl-3,4-dihydrochromene-2-carboxylic acid Chemical compound O1C(C)(C(O)=O)CCC2=C(C)C(OC(=O)C)=C(C)C(C)=C21 CUHJERIEOYEEOS-UHFFFAOYSA-N 0.000 description 2
VMEGFMNVSYVVOM-UHFFFAOYSA-N 6-decylubiquinone Chemical compound CCCCCCCCCCC1=C(C)C(=O)C(OC)=C(OC)C1=O VMEGFMNVSYVVOM-UHFFFAOYSA-N 0.000 description 2
ZDNGYFKANRDTCD-UHFFFAOYSA-N 6-hydroxy-2,5,7,8-tetramethyl-n-(2-pyridin-2-ylethyl)-3,4-dihydrochromene-2-carboxamide Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)C(=O)NCCC1=CC=CC=N1 ZDNGYFKANRDTCD-UHFFFAOYSA-N 0.000 description 2
XVFQBRPTYPJBPP-UHFFFAOYSA-N 6-hydroxy-2,5,7,8-tetramethyl-n-(3-morpholin-4-ylpropyl)-3,4-dihydrochromene-2-carboxamide Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)C(=O)NCCCN1CCOCC1 XVFQBRPTYPJBPP-UHFFFAOYSA-N 0.000 description 2
FKQRJRBJQOHHRN-UHFFFAOYSA-N 6-hydroxy-2,5,7,8-tetramethyl-n-(pyridin-2-ylmethyl)-3,4-dihydrochromene-2-carboxamide Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)C(=O)NCC1=CC=CC=N1 FKQRJRBJQOHHRN-UHFFFAOYSA-N 0.000 description 2
AKMFFCTZUUVDND-UHFFFAOYSA-N 6-hydroxy-2,5,7,8-tetramethyl-n-[3-(2-oxopyrrolidin-1-yl)propyl]-3,4-dihydrochromene-2-carboxamide Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)C(=O)NCCCN1CCCC1=O AKMFFCTZUUVDND-UHFFFAOYSA-N 0.000 description 2
MIYGPTPFHANOGL-UHFFFAOYSA-N 6-hydroxy-2,5,7,8-tetramethyl-n-propyl-3,4-dihydrochromene-2-carboxamide Chemical compound OC1=C(C)C(C)=C2OC(C(=O)NCCC)(C)CCC2=C1C MIYGPTPFHANOGL-UHFFFAOYSA-N 0.000 description 2
HYDIPFCEUJQXIH-UHFFFAOYSA-N 6-hydroxy-n,n,2,5,7,8-hexamethyl-3,4-dihydrochromene-2-carboxamide Chemical compound OC1=C(C)C(C)=C2OC(C(=O)N(C)C)(C)CCC2=C1C HYDIPFCEUJQXIH-UHFFFAOYSA-N 0.000 description 2
AYJMGUNMVOVXSE-UHFFFAOYSA-N 6-hydroxy-n-(1-hydroxypropan-2-yl)-2,5,7,8-tetramethyl-3,4-dihydrochromene-2-carboxamide Chemical compound OC1=C(C)C(C)=C2OC(C(=O)NC(CO)C)(C)CCC2=C1C AYJMGUNMVOVXSE-UHFFFAOYSA-N 0.000 description 2
BFATWCQXCJEFFQ-UHFFFAOYSA-N 6-hydroxy-n-(2-hydroxyethyl)-2,5,7,8-tetramethyl-3,4-dihydrochromene-2-carboxamide Chemical compound O1C(C)(C(=O)NCCO)CCC2=C1C(C)=C(C)C(O)=C2C BFATWCQXCJEFFQ-UHFFFAOYSA-N 0.000 description 2
SBZCZZFEMPCUME-UHFFFAOYSA-N 6-hydroxy-n-(2-methoxyethyl)-2,5,7,8-tetramethyl-3,4-dihydrochromene-2-carboxamide Chemical compound OC1=C(C)C(C)=C2OC(C(=O)NCCOC)(C)CCC2=C1C SBZCZZFEMPCUME-UHFFFAOYSA-N 0.000 description 2
MXHJBGQRROTDIH-UHFFFAOYSA-N 6-hydroxy-n-(3-hydroxypropyl)-2,5,7,8-tetramethyl-3,4-dihydrochromene-2-carboxamide Chemical compound O1C(C)(C(=O)NCCCO)CCC2=C1C(C)=C(C)C(O)=C2C MXHJBGQRROTDIH-UHFFFAOYSA-N 0.000 description 2
YWIFRCMFIXKSGO-UHFFFAOYSA-N 6-hydroxy-n-(5-hydroxypentyl)-2,5,7,8-tetramethyl-3,4-dihydrochromene-2-carboxamide Chemical compound O1C(C)(C(=O)NCCCCCO)CCC2=C1C(C)=C(C)C(O)=C2C YWIFRCMFIXKSGO-UHFFFAOYSA-N 0.000 description 2
SRZKZESSIMXMIH-UHFFFAOYSA-N 6-hydroxy-n-[2-(4-hydroxyphenyl)ethyl]-2,5,7,8-tetramethyl-3,4-dihydrochromene-2-carboxamide Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)C(=O)NCCC1=CC=C(O)C=C1 SRZKZESSIMXMIH-UHFFFAOYSA-N 0.000 description 2
HOFLDQRKBZIPRU-UHFFFAOYSA-N 6-hydroxy-n-methoxy-n,2,5,7,8-pentamethyl-3,4-dihydrochromene-2-carboxamide Chemical compound OC1=C(C)C(C)=C2OC(C(=O)N(C)OC)(C)CCC2=C1C HOFLDQRKBZIPRU-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
206010008025 Cerebellar ataxia Diseases 0.000 description 2
206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 2
201000000915 Chronic Progressive External Ophthalmoplegia Diseases 0.000 description 2
206010010356 Congenital anomaly Diseases 0.000 description 2
229920000858 Cyclodextrin Polymers 0.000 description 2
201000003883 Cystic fibrosis Diseases 0.000 description 2
208000002155 Cytochrome-c Oxidase Deficiency Diseases 0.000 description 2
208000014094 Dystonic disease Diseases 0.000 description 2
206010014561 Emphysema Diseases 0.000 description 2
101800003838 Epidermal growth factor Proteins 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
YPZRHBJKEMOYQH-UYBVJOGSSA-L FADH2(2-) Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP([O-])(=O)OP([O-])(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C(NC(=O)NC2=O)=C2NC2=C1C=C(C)C(C)=C2 YPZRHBJKEMOYQH-UYBVJOGSSA-L 0.000 description 2
102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 2
102000003869 Frataxin Human genes 0.000 description 2
108090000217 Frataxin Proteins 0.000 description 2
208000028782 Hereditary disease Diseases 0.000 description 2
QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical group C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
208000019693 Lung disease Diseases 0.000 description 2
206010058467 Lung neoplasm malignant Diseases 0.000 description 2
208000009564 MELAS Syndrome Diseases 0.000 description 2
208000024556 Mendelian disease Diseases 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
102000036675 Myoglobin Human genes 0.000 description 2
108010062374 Myoglobin Proteins 0.000 description 2
206010033799 Paralysis Diseases 0.000 description 2
208000027089 Parkinsonian disease Diseases 0.000 description 2
206010034010 Parkinsonism Diseases 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
206010034620 Peripheral sensory neuropathy Diseases 0.000 description 2
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Chemical group C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical group N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
208000007014 Retinitis pigmentosa Diseases 0.000 description 2
208000020221 Short stature Diseases 0.000 description 2
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
206010044565 Tremor Diseases 0.000 description 2
HGBRUSZDRNEVPA-UHFFFAOYSA-N [2-(hexylcarbamoyl)-2,5,7,8-tetramethyl-3,4-dihydrochromen-6-yl] acetate Chemical compound CC(=O)OC1=C(C)C(C)=C2OC(C(=O)NCCCCCC)(C)CCC2=C1C HGBRUSZDRNEVPA-UHFFFAOYSA-N 0.000 description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000000654 additive Substances 0.000 description 2
238000003915 air pollution Methods 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
230000003078 antioxidant effect Effects 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
238000011325 biochemical measurement Methods 0.000 description 2
230000003851 biochemical process Effects 0.000 description 2
210000001124 body fluid Anatomy 0.000 description 2
239000010839 body fluid Substances 0.000 description 2
239000001273 butane Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000006143 cell culture medium Substances 0.000 description 2
230000030833 cell death Effects 0.000 description 2
210000003850 cellular structure Anatomy 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
230000008859 change Effects 0.000 description 2
230000001054 cortical effect Effects 0.000 description 2
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 2
230000007547 defect Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
230000001627 detrimental effect Effects 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
208000010118 dystonia Diseases 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
229940116977 epidermal growth factor Drugs 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
230000005284 excitation Effects 0.000 description 2
230000029142 excretion Effects 0.000 description 2
235000019162 flavin adenine dinucleotide Nutrition 0.000 description 2
239000011714 flavin adenine dinucleotide Substances 0.000 description 2
230000006870 function Effects 0.000 description 2
239000011521 glass Substances 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
229960003180 glutathione Drugs 0.000 description 2
239000008187 granular material Substances 0.000 description 2
COQRGFWWJBEXRC-UHFFFAOYSA-N hydron;methyl 2-aminoacetate;chloride Chemical compound Cl.COC(=O)CN COQRGFWWJBEXRC-UHFFFAOYSA-N 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
229940011051 isopropyl acetate Drugs 0.000 description 2
150000003893 lactate salts Chemical class 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
201000005202 lung cancer Diseases 0.000 description 2
208000020816 lung neoplasm Diseases 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000002595 magnetic resonance imaging Methods 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
235000020938 metabolic status Nutrition 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
125000006431 methyl cyclopropyl group Chemical group 0.000 description 2
230000002438 mitochondrial effect Effects 0.000 description 2
210000001700 mitochondrial membrane Anatomy 0.000 description 2
239000003068 molecular probe Substances 0.000 description 2
208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
GNUWFWUNTMBWKG-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide Chemical compound CN(C)CCNC(=O)C(C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O GNUWFWUNTMBWKG-UHFFFAOYSA-N 0.000 description 2
YHDLWWYVEKBXTD-UHFFFAOYSA-N n-benzyl-6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromene-2-carboxamide Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)C(=O)NCC1=CC=CC=C1 YHDLWWYVEKBXTD-UHFFFAOYSA-N 0.000 description 2
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
HZKPFWBHBGIULH-UHFFFAOYSA-N n-ethyl-6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromene-2-carboxamide Chemical compound OC1=C(C)C(C)=C2OC(C(=O)NCC)(C)CCC2=C1C HZKPFWBHBGIULH-UHFFFAOYSA-N 0.000 description 2
NHBIOXLONQGSBU-UHFFFAOYSA-N n-ethyl-6-hydroxy-n,2,5,7,8-pentamethyl-3,4-dihydrochromene-2-carboxamide Chemical compound OC1=C(C)C(C)=C2OC(C(=O)N(C)CC)(C)CCC2=C1C NHBIOXLONQGSBU-UHFFFAOYSA-N 0.000 description 2
OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
GHQCANALYFAXLT-UHFFFAOYSA-N n-tert-butyl-6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromene-2-carboxamide Chemical compound O1C(C)(C(=O)NC(C)(C)C)CCC2=C1C(C)=C(C)C(O)=C2C GHQCANALYFAXLT-UHFFFAOYSA-N 0.000 description 2
XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
230000000626 neurodegenerative effect Effects 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000000346 nonvolatile oil Substances 0.000 description 2
108010007425 oligomycin sensitivity conferring protein Proteins 0.000 description 2
239000010502 orange oil Substances 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
208000021090 palsy Diseases 0.000 description 2
210000000496 pancreas Anatomy 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
238000003359 percent control normalization Methods 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
239000002243 precursor Substances 0.000 description 2
230000002028 premature Effects 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
238000012545 processing Methods 0.000 description 2
239000000651 prodrug Substances 0.000 description 2
229940002612 prodrug Drugs 0.000 description 2
239000000047 product Substances 0.000 description 2
230000000644 propagated effect Effects 0.000 description 2
WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000027756 respiratory electron transport chain Effects 0.000 description 2
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
201000005572 sensory peripheral neuropathy Diseases 0.000 description 2
238000013207 serial dilution Methods 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
210000001626 skin fibroblast Anatomy 0.000 description 2
239000007909 solid dosage form Substances 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000007858 starting material Substances 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
238000004659 sterilization and disinfection Methods 0.000 description 2
229960005322 streptomycin Drugs 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000012546 transfer Methods 0.000 description 2
230000009466 transformation Effects 0.000 description 2
230000008733 trauma Effects 0.000 description 2
DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
JJRHJDUELSYTPF-MRXNPFEDSA-N (2r)-2-hydroxy-n-(2-hydroxyethyl)-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide Chemical compound CC1=C(C)C(=O)C(CC[C@@](C)(O)C(=O)NCCO)=C(C)C1=O JJRHJDUELSYTPF-MRXNPFEDSA-N 0.000 description 1
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
LAXXPOJCFVMVAX-ZETCQYMHSA-N (2s)-2-amino-4-butylsulfanylbutanoic acid Chemical compound CCCCSCC[C@H](N)C(O)=O LAXXPOJCFVMVAX-ZETCQYMHSA-N 0.000 description 1
BAANPNDZFYBQIB-AWEZNQCLSA-N (2s)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide Chemical compound CC1=C(C)C(=O)C(CC[C@](C)(O)C(N)=O)=C(C)C1=O BAANPNDZFYBQIB-AWEZNQCLSA-N 0.000 description 1
JJRHJDUELSYTPF-INIZCTEOSA-N (2s)-2-hydroxy-n-(2-hydroxyethyl)-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide Chemical compound CC1=C(C)C(=O)C(CC[C@](C)(O)C(=O)NCCO)=C(C)C1=O JJRHJDUELSYTPF-INIZCTEOSA-N 0.000 description 1
BFATWCQXCJEFFQ-INIZCTEOSA-N (2s)-6-hydroxy-n-(2-hydroxyethyl)-2,5,7,8-tetramethyl-3,4-dihydrochromene-2-carboxamide Chemical compound O1[C@](C)(C(=O)NCCO)CCC2=C1C(C)=C(C)C(O)=C2C BFATWCQXCJEFFQ-INIZCTEOSA-N 0.000 description 1
WEJRCMABQSYFIT-UHFFFAOYSA-N (4-benzylpiperazin-1-yl)-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methanone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)C(=O)N(CC1)CCN1CC1=CC=CC=C1 WEJRCMABQSYFIT-UHFFFAOYSA-N 0.000 description 1
FDOLAMRYHDWRIS-UHFFFAOYSA-N (4-methylpiperazin-1-yl)methanone Chemical compound CN1CCN([C]=O)CC1 FDOLAMRYHDWRIS-UHFFFAOYSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical group C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical group C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
HJORCZCMNWLHMB-UHFFFAOYSA-N 1-(3-aminopropyl)pyrrolidin-2-one Chemical compound NCCCN1CCCC1=O HJORCZCMNWLHMB-UHFFFAOYSA-N 0.000 description 1
PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical compound CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 description 1
IQXXEPZFOOTTBA-UHFFFAOYSA-N 1-benzylpiperazine Chemical compound C=1C=CC=CC=1CN1CCNCC1 IQXXEPZFOOTTBA-UHFFFAOYSA-N 0.000 description 1
PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 1
HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical group C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
DDZGQYREBDXECY-UHFFFAOYSA-N 1h-pyrazolo[3,4-b]pyrazine Chemical compound C1=CN=C2C=NNC2=N1 DDZGQYREBDXECY-UHFFFAOYSA-N 0.000 description 1
RVSIYTLODOLVKA-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanol Chemical compound NCCOCCO.NCCOCCO RVSIYTLODOLVKA-UHFFFAOYSA-N 0.000 description 1
WOXFMYVTSLAQMO-UHFFFAOYSA-N 2-Pyridinemethanamine Chemical compound NCC1=CC=CC=N1 WOXFMYVTSLAQMO-UHFFFAOYSA-N 0.000 description 1
YQWBZLQPLUEHID-UHFFFAOYSA-N 2-[3-hydroxy-3-methyl-4-(4-methylpiperazin-1-yl)-4-oxobutyl]-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione Chemical compound C1CN(C)CCN1C(=O)C(C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O YQWBZLQPLUEHID-UHFFFAOYSA-N 0.000 description 1
HHCFBRMRTMTSHY-UHFFFAOYSA-N 2-[3-hydroxy-4-(4-hydroxypiperidin-1-yl)-3-methyl-4-oxobutyl]-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C(C)=C(C)C(=O)C(CCC(C)(O)C(=O)N2CCC(O)CC2)=C1C HHCFBRMRTMTSHY-UHFFFAOYSA-N 0.000 description 1
VDQYQSWPEIJUKH-UHFFFAOYSA-N 2-[4-(4-fluoropiperidin-1-yl)-3-hydroxy-3-methyl-4-oxobutyl]-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C(C)=C(C)C(=O)C(CCC(C)(O)C(=O)N2CCC(F)CC2)=C1C VDQYQSWPEIJUKH-UHFFFAOYSA-N 0.000 description 1
IBQDEFFOOZANGJ-UHFFFAOYSA-N 2-[4-(azepan-1-yl)-3-hydroxy-3-methyl-4-oxobutyl]-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C(C)=C(C)C(=O)C(CCC(C)(O)C(=O)N2CCCCCC2)=C1C IBQDEFFOOZANGJ-UHFFFAOYSA-N 0.000 description 1
BKMMTJMQCTUHRP-UHFFFAOYSA-N 2-aminopropan-1-ol Chemical compound CC(N)CO BKMMTJMQCTUHRP-UHFFFAOYSA-N 0.000 description 1
CDVRPNAGCXXGTM-UHFFFAOYSA-N 2-hydroxy-2-methyl-n-(2-methylpropyl)-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide Chemical compound CC(C)CNC(=O)C(C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O CDVRPNAGCXXGTM-UHFFFAOYSA-N 0.000 description 1
OBDPZTIURVLZSL-UHFFFAOYSA-N 2-hydroxy-2-methyl-n-(2-phenylethyl)-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide Chemical compound O=C1C(C)=C(C)C(=O)C(CCC(C)(O)C(=O)NCCC=2C=CC=CC=2)=C1C OBDPZTIURVLZSL-UHFFFAOYSA-N 0.000 description 1
PLNRBIZXDTUKSQ-UHFFFAOYSA-N 2-hydroxy-2-methyl-n-(3-methylbutyl)-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide Chemical compound CC(C)CCNC(=O)C(C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O PLNRBIZXDTUKSQ-UHFFFAOYSA-N 0.000 description 1
WPNCZUXRTXNUOT-UHFFFAOYSA-N 2-hydroxy-2-methyl-n-(3-morpholin-4-ylpropyl)-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide Chemical compound O=C1C(C)=C(C)C(=O)C(CCC(C)(O)C(=O)NCCCN2CCOCC2)=C1C WPNCZUXRTXNUOT-UHFFFAOYSA-N 0.000 description 1
ODQUVCGQJDOISS-UHFFFAOYSA-N 2-hydroxy-2-methyl-n-propyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide Chemical compound CCCNC(=O)C(C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O ODQUVCGQJDOISS-UHFFFAOYSA-N 0.000 description 1
FIFGTTTWBCKJMR-UHFFFAOYSA-N 2-hydroxy-n,n,2-trimethyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide Chemical compound CN(C)C(=O)C(C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O FIFGTTTWBCKJMR-UHFFFAOYSA-N 0.000 description 1
JJRHJDUELSYTPF-UHFFFAOYSA-N 2-hydroxy-n-(2-hydroxyethyl)-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide Chemical compound CC1=C(C)C(=O)C(CCC(C)(O)C(=O)NCCO)=C(C)C1=O JJRHJDUELSYTPF-UHFFFAOYSA-N 0.000 description 1
SIPLUPOCGVTMNA-UHFFFAOYSA-N 2-hydroxy-n-(3-hydroxypropyl)-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide Chemical compound CC1=C(C)C(=O)C(CCC(C)(O)C(=O)NCCCO)=C(C)C1=O SIPLUPOCGVTMNA-UHFFFAOYSA-N 0.000 description 1
BRGNSBSIUIKKLP-UHFFFAOYSA-N 2-hydroxy-n-(5-hydroxypentyl)-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide Chemical compound CC1=C(C)C(=O)C(CCC(C)(O)C(=O)NCCCCCO)=C(C)C1=O BRGNSBSIUIKKLP-UHFFFAOYSA-N 0.000 description 1
OQLUSMGVSCTTCH-UHFFFAOYSA-N 2-hydroxy-n-[2-(4-hydroxyphenyl)ethyl]-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide Chemical compound O=C1C(C)=C(C)C(=O)C(CCC(C)(O)C(=O)NCCC=2C=CC(O)=CC=2)=C1C OQLUSMGVSCTTCH-UHFFFAOYSA-N 0.000 description 1
125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical group C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
PFDDBXPXNRGYDV-UHFFFAOYSA-N 3-morpholin-3-ylpropan-1-amine Chemical compound NCCCC1COCCN1 PFDDBXPXNRGYDV-UHFFFAOYSA-N 0.000 description 1
BLFRQYKZFKYQLO-UHFFFAOYSA-N 4-aminobutan-1-ol Chemical compound NCCCCO BLFRQYKZFKYQLO-UHFFFAOYSA-N 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
LQGKDMHENBFVRC-UHFFFAOYSA-N 5-aminopentan-1-ol Chemical compound NCCCCCO LQGKDMHENBFVRC-UHFFFAOYSA-N 0.000 description 1
SUTWPJHCRAITLU-UHFFFAOYSA-N 6-aminohexan-1-ol Chemical compound NCCCCCCO SUTWPJHCRAITLU-UHFFFAOYSA-N 0.000 description 1
XCJWJZLUWFUQCN-UHFFFAOYSA-N 6-hydroxy-2,5,7,8-tetramethyl-n-(2-phenylethyl)-3,4-dihydrochromene-2-carboxamide Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)C(=O)NCCC1=CC=CC=C1 XCJWJZLUWFUQCN-UHFFFAOYSA-N 0.000 description 1
RLXCERRJVUPLCH-UHFFFAOYSA-N 6-hydroxy-2,5,7,8-tetramethyl-n-(oxolan-2-ylmethyl)-3,4-dihydrochromene-2-carboxamide Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)C(=O)NCC1CCCO1 RLXCERRJVUPLCH-UHFFFAOYSA-N 0.000 description 1
DHGQCPPGGBDFEH-UHFFFAOYSA-N 6-hydroxy-n,n-bis(2-hydroxyethyl)-2,5,7,8-tetramethyl-3,4-dihydrochromene-2-carboxamide Chemical compound O1C(C)(C(=O)N(CCO)CCO)CCC2=C1C(C)=C(C)C(O)=C2C DHGQCPPGGBDFEH-UHFFFAOYSA-N 0.000 description 1
BYVXPZSZIRKAHU-UHFFFAOYSA-N 6-hydroxy-n-(2-hydroxypropyl)-2,5,7,8-tetramethyl-3,4-dihydrochromene-2-carboxamide Chemical compound OC1=C(C)C(C)=C2OC(C(=O)NCC(O)C)(C)CCC2=C1C BYVXPZSZIRKAHU-UHFFFAOYSA-N 0.000 description 1
FBTPJYNQGXQBNG-UHFFFAOYSA-N 6-hydroxy-n-(4-hydroxybutyl)-2,5,7,8-tetramethyl-3,4-dihydrochromene-2-carboxamide Chemical compound O1C(C)(C(=O)NCCCCO)CCC2=C1C(C)=C(C)C(O)=C2C FBTPJYNQGXQBNG-UHFFFAOYSA-N 0.000 description 1
WXRMHPJCWLRFPQ-UHFFFAOYSA-N 6-hydroxy-n-(6-hydroxyhexyl)-2,5,7,8-tetramethyl-3,4-dihydrochromene-2-carboxamide Chemical compound O1C(C)(C(=O)NCCCCCCO)CCC2=C1C(C)=C(C)C(O)=C2C WXRMHPJCWLRFPQ-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
206010069754 Acquired gene mutation Diseases 0.000 description 1
ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
101100007300 Caenorhabditis elegans coq-2 gene Proteins 0.000 description 1
241000283707 Capra Species 0.000 description 1
208000002061 Cardiac Conduction System Disease Diseases 0.000 description 1
208000002177 Cataract Diseases 0.000 description 1
206010008027 Cerebellar atrophy Diseases 0.000 description 1
206010008190 Cerebrovascular accident Diseases 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
208000027205 Congenital disease Diseases 0.000 description 1
208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 description 1
HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
ZAKOWWREFLAJOT-UHFFFAOYSA-N DL-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
230000005971 DNA damage repair Effects 0.000 description 1
206010011891 Deafness neurosensory Diseases 0.000 description 1
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
208000012239 Developmental disease Diseases 0.000 description 1
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
208000012661 Dyskinesia Diseases 0.000 description 1
208000000059 Dyspnea Diseases 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
102000008013 Electron Transport Complex I Human genes 0.000 description 1
108010089760 Electron Transport Complex I Proteins 0.000 description 1
241000792859 Enema Species 0.000 description 1
OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
MBMLMWLHJBBADN-UHFFFAOYSA-N Ferrous sulfide Chemical class [Fe]=S MBMLMWLHJBBADN-UHFFFAOYSA-N 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
102000006587 Glutathione peroxidase Human genes 0.000 description 1
108700016172 Glutathione peroxidases Proteins 0.000 description 1
101710101434 Glutathione synthetase Proteins 0.000 description 1
102100034294 Glutathione synthetase Human genes 0.000 description 1
101710087514 Glutathione synthetase, chloroplastic Proteins 0.000 description 1
206010053759 Growth retardation Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
206010020660 Hyperlactacidaemia Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
208000000038 Hypoparathyroidism Diseases 0.000 description 1
WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical group C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
208000015592 Involuntary movements Diseases 0.000 description 1
208000032382 Ischaemic stroke Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
201000003533 Leber congenital amaurosis Diseases 0.000 description 1
206010024264 Lethargy Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
208000036626 Mental retardation Diseases 0.000 description 1
108020005196 Mitochondrial DNA Proteins 0.000 description 1
206010052641 Mitochondrial DNA mutation Diseases 0.000 description 1
108010085220 Multiprotein Complexes Proteins 0.000 description 1
102000007474 Multiprotein Complexes Human genes 0.000 description 1
101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 1
208000002740 Muscle Rigidity Diseases 0.000 description 1
208000010428 Muscle Weakness Diseases 0.000 description 1
206010049565 Muscle fatigue Diseases 0.000 description 1
206010028372 Muscular weakness Diseases 0.000 description 1
208000036572 Myoclonic epilepsy Diseases 0.000 description 1
208000002033 Myoclonus Diseases 0.000 description 1
206010028629 Myoglobinuria Diseases 0.000 description 1
BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
102000006746 NADH Dehydrogenase Human genes 0.000 description 1
108010086428 NADH Dehydrogenase Proteins 0.000 description 1
206010061309 Neoplasm progression Diseases 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
206010060860 Neurological symptom Diseases 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
235000019502 Orange oil Nutrition 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
208000036757 Postencephalitic parkinsonism Diseases 0.000 description 1
WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
239000004365 Protease Substances 0.000 description 1
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
WHBMMWSBFZVSSR-UHFFFAOYSA-N R3HBA Natural products CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
206010038910 Retinitis Diseases 0.000 description 1
241000219061 Rheum Species 0.000 description 1
229910005946 SO2 Cr Inorganic materials 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
235000019485 Safflower oil Nutrition 0.000 description 1
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
208000009966 Sensorineural Hearing Loss Diseases 0.000 description 1
208000032023 Signs and Symptoms Diseases 0.000 description 1
208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
208000010112 Spinocerebellar Degenerations Diseases 0.000 description 1
102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical group C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
229930003427 Vitamin E Chemical class 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000032683 aging Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
238000010171 animal model Methods 0.000 description 1
125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
238000000668 atmospheric pressure chemical ionisation mass spectrometry Methods 0.000 description 1
125000003725 azepanyl group Chemical group 0.000 description 1
HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical group CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
239000012964 benzotriazole Substances 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
UUQMNUMQCIQDMZ-UHFFFAOYSA-N betahistine Chemical compound CNCCC1=CC=CC=N1 UUQMNUMQCIQDMZ-UHFFFAOYSA-N 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
238000010256 biochemical assay Methods 0.000 description 1
230000008238 biochemical pathway Effects 0.000 description 1
238000005842 biochemical reaction Methods 0.000 description 1
238000010876 biochemical test Methods 0.000 description 1
230000002715 bioenergetic effect Effects 0.000 description 1
239000012472 biological sample Substances 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
208000030303 breathing problems Diseases 0.000 description 1
239000012267 brine Substances 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
108010079785 calpain inhibitors Proteins 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
210000004289 cerebral ventricle Anatomy 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
238000010568 chiral column chromatography Methods 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000009194 climbing Effects 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
230000000112 colonic effect Effects 0.000 description 1
239000012230 colorless oil Substances 0.000 description 1
230000009514 concussion Effects 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
239000000599 controlled substance Substances 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
229910000365 copper sulfate Inorganic materials 0.000 description 1
ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000013058 crude material Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
208000026615 cytochrome-c oxidase deficiency disease Diseases 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
238000006392 deoxygenation reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
229910052805 deuterium Inorganic materials 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
201000009028 early myoclonic encephalopathy Diseases 0.000 description 1
238000000840 electrochemical analysis Methods 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
230000037149 energy metabolism Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
LIWAQLJGPBVORC-UHFFFAOYSA-N ethylmethylamine Chemical compound CCNC LIWAQLJGPBVORC-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
231100000318 excitotoxic Toxicity 0.000 description 1
230000003492 excitotoxic effect Effects 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 1
229940093632 flavin-adenine dinucleotide Drugs 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000012634 fragment Substances 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Chemical class CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000007429 general method Methods 0.000 description 1
238000010448 genetic screening Methods 0.000 description 1
230000004153 glucose metabolism Effects 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
230000012010 growth Effects 0.000 description 1
231100000001 growth retardation Toxicity 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
230000004217 heart function Effects 0.000 description 1
201000003636 hereditary ataxia Diseases 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
125000000687 hydroquinonyl group Chemical group C1(O)=C(C=C(O)C=C1)* 0.000 description 1
230000001660 hyperkinetic effect Effects 0.000 description 1
125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical group C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
150000005232 imidazopyridines Chemical class 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Chemical group CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Chemical group C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
108700005859 infantile histiocytoid Cardiomyopathy Proteins 0.000 description 1
201000010990 infantile histiocytoid cardiomyopathy Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
229940102213 injectable suspension Drugs 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
230000002262 irrigation Effects 0.000 description 1
238000003973 irrigation Methods 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical group C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
229940001447 lactate Drugs 0.000 description 1
230000006651 lactation Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000003140 lateral ventricle Anatomy 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000004973 liquid crystal related substance Substances 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
210000002311 liver mitochondria Anatomy 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
230000037323 metabolic rate Effects 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
229960001252 methamphetamine Drugs 0.000 description 1
VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
GYZJOOCNMNYKKK-UHFFFAOYSA-N methyl 2-[[2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanoyl]amino]acetate Chemical compound COC(=O)CNC(=O)C(C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O GYZJOOCNMNYKKK-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
230000004898 mitochondrial function Effects 0.000 description 1
230000006705 mitochondrial oxidative phosphorylation Effects 0.000 description 1
230000010021 mitochondrial pathology Effects 0.000 description 1
239000003607 modifier Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
230000004973 motor coordination Effects 0.000 description 1
238000001964 muscle biopsy Methods 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 1
AHIQKWGYOKSDII-UHFFFAOYSA-N n-(4-amino-1-methyl-2,6-dioxo-3-phenylpyrimidin-5-yl)-4-(2,5-dihydroxy-3,4,6-trimethylphenyl)-2-hydroxy-2-methylbutanamide Chemical compound CC1=C(O)C(C)=C(C)C(O)=C1CCC(C)(O)C(=O)NC(C(N(C)C1=O)=O)=C(N)N1C1=CC=CC=C1 AHIQKWGYOKSDII-UHFFFAOYSA-N 0.000 description 1
OOQRZEHMOGEIMJ-UHFFFAOYSA-N n-(cyclopropylmethyl)-6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromene-2-carboxamide Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)C(=O)NCC1CC1 OOQRZEHMOGEIMJ-UHFFFAOYSA-N 0.000 description 1
CZLFJJBVYRVJQE-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide;hydrochloride Chemical compound Cl.CN(C)CCNC(=O)C(C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O CZLFJJBVYRVJQE-UHFFFAOYSA-N 0.000 description 1
SFIIZOBFOCEAII-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromene-2-carboxamide Chemical compound OC1=C(C)C(C)=C2OC(C(=O)NCCN(C)C)(C)CCC2=C1C SFIIZOBFOCEAII-UHFFFAOYSA-N 0.000 description 1
XZPHOPZWQOTSKF-UHFFFAOYSA-N n-hexyl-6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromene-2-carboxamide Chemical compound OC1=C(C)C(C)=C2OC(C(=O)NCCCCCC)(C)CCC2=C1C XZPHOPZWQOTSKF-UHFFFAOYSA-N 0.000 description 1
WCOPNZHOYZMZQH-UHFFFAOYSA-N n-tert-butyl-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide Chemical compound CC1=C(C)C(=O)C(CCC(C)(O)C(=O)NC(C)(C)C)=C(C)C1=O WCOPNZHOYZMZQH-UHFFFAOYSA-N 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
210000002850 nasal mucosa Anatomy 0.000 description 1
208000009928 nephrosis Diseases 0.000 description 1
231100001027 nephrosis Toxicity 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
238000002610 neuroimaging Methods 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
208000018360 neuromuscular disease Diseases 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
206010029864 nystagmus Diseases 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
208000001749 optic atrophy Diseases 0.000 description 1
238000005457 optimization Methods 0.000 description 1
230000004768 organ dysfunction Effects 0.000 description 1
210000004789 organ system Anatomy 0.000 description 1
210000003463 organelle Anatomy 0.000 description 1
230000001151 other effect Effects 0.000 description 1
230000004783 oxidative metabolism Effects 0.000 description 1
KQOATKAFTRNONV-UHFFFAOYSA-N oxolan-2-amine Chemical compound NC1CCCO1 KQOATKAFTRNONV-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
WEYVCQFUGFRXOM-UHFFFAOYSA-N perazine Chemical class C1CN(C)CCN1CCCN1C2=CC=CC=C2SC2=CC=CC=C21 WEYVCQFUGFRXOM-UHFFFAOYSA-N 0.000 description 1
229960002195 perazine Drugs 0.000 description 1
239000002304 perfume Substances 0.000 description 1
229940117803 phenethylamine Drugs 0.000 description 1
229960003531 phenolsulfonphthalein Drugs 0.000 description 1
125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
150000008105 phosphatidylcholines Chemical class 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 1
150000004885 piperazines Chemical class 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920002635 polyurethane Polymers 0.000 description 1
239000004814 polyurethane Substances 0.000 description 1
238000002600 positron emission tomography Methods 0.000 description 1
208000000170 postencephalitic Parkinson disease Diseases 0.000 description 1
230000001144 postural effect Effects 0.000 description 1
235000015320 potassium carbonate Nutrition 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
230000036515 potency Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
208000025109 proximal renal tubular acidosis Diseases 0.000 description 1
125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical group C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical group C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
150000005229 pyrazolopyridines Chemical class 0.000 description 1
PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
125000006514 pyridin-2-ylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical group N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
125000004151 quinonyl group Chemical group 0.000 description 1
SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical group C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
239000000376 reactant Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000011514 reflex Effects 0.000 description 1
230000002207 retinal effect Effects 0.000 description 1
235000005713 safflower oil Nutrition 0.000 description 1
239000003813 safflower oil Substances 0.000 description 1
238000005070 sampling Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
229910052711 selenium Inorganic materials 0.000 description 1
239000011669 selenium Substances 0.000 description 1
208000023573 sensorineural hearing loss disease Diseases 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
230000035939 shock Effects 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
230000037439 somatic mutation Effects 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000000707 stereoselective effect Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
229930192474 thiophene Chemical group 0.000 description 1
230000009092 tissue dysfunction Effects 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000005751 tumor progression Effects 0.000 description 1
229960003732 tyramine Drugs 0.000 description 1
229940040064 ubiquinol Drugs 0.000 description 1
QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 description 1
230000036325 urinary excretion Effects 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
239000011709 vitamin E Chemical class 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
230000002747 voluntary effect Effects 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
239000001993 wax Substances 0.000 description 1
210000004885 white matter Anatomy 0.000 description 1

Landscapes

Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ES20169398T 2007-11-06 2008-11-04 Derivados de 4-(p-quinonil)-2-hidroxibutanamida para el tratamiento de enfermedades mitocondriales Active ES2980685T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US21270707P	2007-11-06	2007-11-06
US21260707P	2007-11-06	2007-11-06

Publications (1)

Publication Number	Publication Date
ES2980685T3 true ES2980685T3 (es)	2024-10-02

Family

ID=73156426

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
ES20169398T Active ES2980685T3 (es)	2007-11-06	2008-11-04	Derivados de 4-(p-quinonil)-2-hidroxibutanamida para el tratamiento de enfermedades mitocondriales
ES18198941T Active ES2805081T3 (es)	2007-11-06	2008-11-04	Derivados de 4-(p-quinonil)-2-hidroxibutanamida para el tratamiento de enfermedades mitocondriales

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
ES18198941T Active ES2805081T3 (es)	2007-11-06	2008-11-04	Derivados de 4-(p-quinonil)-2-hidroxibutanamida para el tratamiento de enfermedades mitocondriales

Country Status (9)

Country	Link
DK (1)	DK3733642T3 (pl)
ES (2)	ES2980685T3 (pl)
FI (1)	FI3733642T3 (pl)
HR (1)	HRP20240966T3 (pl)
HU (2)	HUE051366T2 (pl)
LT (1)	LT3733642T (pl)
PL (1)	PL3733642T3 (pl)
PT (2)	PT3733642T (pl)
SI (1)	SI3733642T1 (pl)

2008
- 2008-11-04 SI SI200832220T patent/SI3733642T1/sl unknown
- 2008-11-04 PT PT201693983T patent/PT3733642T/pt unknown
- 2008-11-04 PL PL20169398.3T patent/PL3733642T3/pl unknown
- 2008-11-04 HU HUE18198941A patent/HUE051366T2/hu unknown
- 2008-11-04 HR HRP20240966TT patent/HRP20240966T3/hr unknown
- 2008-11-04 HU HUE20169398A patent/HUE067771T2/hu unknown
- 2008-11-04 DK DK20169398.3T patent/DK3733642T3/da active
- 2008-11-04 LT LTEP20169398.3T patent/LT3733642T/lt unknown
- 2008-11-04 ES ES20169398T patent/ES2980685T3/es active Active
- 2008-11-04 FI FIEP20169398.3T patent/FI3733642T3/fi active
- 2008-11-04 ES ES18198941T patent/ES2805081T3/es active Active
- 2008-11-04 PT PT181989419T patent/PT3456707T/pt unknown

Also Published As

Publication number	Publication date
HUE067771T2 (hu)	2024-11-28
HRP20240966T3 (hr)	2024-10-25
PT3733642T (pt)	2024-06-17
SI3733642T1 (sl)	2024-08-30
ES2805081T3 (es)	2021-02-10
DK3733642T3 (da)	2024-08-12
LT3733642T (lt)	2024-06-10
PL3733642T3 (pl)	2024-07-29
FI3733642T3 (fi)	2024-07-19
PT3456707T (pt)	2020-07-09
HUE051366T2 (hu)	2021-03-01

Publication	Publication Date	Title
US11840497B2 (en)	2023-12-12	4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
US9090576B2 (en)	2015-07-28	2-substituted-p-quinone derivatives for treatment of oxidative stress diseases
JP2011503005A5 (pl)	2012-12-20
EP3971182B1 (en)	2026-04-01	2-substituted amino-naphth[1,2-d]imidazol-5-one compounds or pharmaceutically acceptable salts thereof
ES2980685T3 (es)	2024-10-02	Derivados de 4-(p-quinonil)-2-hidroxibutanamida para el tratamiento de enfermedades mitocondriales
HK40010622A (en)	2020-07-10	4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
HK40010622B (en)	2021-01-29	4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
HK1143804B (en)	2016-06-17	4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
HK40015214B (en)	2022-05-20	2-substituted amino-naphth[1,2-d]imidazol-5-one compounds or pharmaceutically acceptable salts thereof
HK40015214A (en)	2020-08-28	2-substituted amino-naphth[1,2-d]imidazol-5-one compounds or pharmaceutically acceptable salts thereof